Allianz Asset Management GmbH Grows Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Allianz Asset Management GmbH boosted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 68.2% in the 4th quarter, Holdings Channel reports. The fund owned 598,832 shares of the specialty pharmaceutical company’s stock after purchasing an additional 242,892 shares during the period. Allianz Asset Management GmbH’s holdings in Jazz Pharmaceuticals were worth $101,801,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hilltop National Bank purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $36,000. LRI Investments LLC purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $38,000. Danske Bank A S purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $40,000. Geneos Wealth Management Inc. grew its stake in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 332 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on JAZZ. Sanford C. Bernstein reissued a “market perform” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday. Barclays boosted their price objective on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Truist Financial set a $256.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Finally, UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $246.06.

Insiders Place Their Bets

In other news, Director Rick E. Winningham sold 2,741 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.57, for a total value of $662,143.37. Following the completion of the sale, the director owned 9,567 shares of the company’s stock, valued at approximately $2,311,100.19. The trade was a 22.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the completion of the sale, the director directly owned 384,682 shares of the company’s stock, valued at $73,281,921. The trade was a 1.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 10,741 shares of company stock worth $2,287,143 in the last quarter. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $229.63 on Thursday. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. The firm has a market capitalization of $14.43 billion, a price-to-earnings ratio of -11,475.76, a PEG ratio of 0.22 and a beta of 0.32. The firm’s fifty day simple moving average is $215.82 and its 200 day simple moving average is $188.13. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business had revenue of $1.07 billion for the quarter. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 21.59 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.